BioCentury
ARTICLE | Company News

Genentech terminates NewLink collaboration for IDO, TDO inhibitors

May 18, 2018 7:07 PM UTC

NewLink Genetics Corp. (NASDAQ:NLNK) said in an SEC filing that the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) terminated the remaining portion of a 2014 research collaboration that covered the development of next-generation indoleamine 2,3-dioxygenase (IDO; INDO) and tryptophan 2,3-dioxygenase (TDO; TDO2) inhibitors.

As a result of the termination, Genentech will grant NewLink, exclusive, worldwide rights to develop and commercialize compounds generated under the agreement. Genentech will be eligible for low single-digit royalties...